Dun & Bradstreet Holdings, Inc.
—- Market cap
- —
- Debt
- +$3.53B
- Cash
- −$205.90M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: DNB stock price vs MORN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MORN's multiple
Needs MORN P/S.
Implied fair value · at DNB's multiple
Needs DNB P/S.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Dun & Bradstreet Holdings, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
MORNINGSTAR, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
EQUIFAX INC
DNB vs EFX
FAIR ISAAC CORP
DNB vs FICO
TransUnion
DNB vs TRU
Root, Inc.
DNB vs ROOT
Xerox Holdings Corp
DNB vs XRX
FACTSET RESEARCH SYSTEMS INC
DNB vs FDS
MOODYS CORP /DE/
DNB vs MCO
BROADRIDGE FINANCIAL SOLUTIONS, INC.
DNB vs BR
MSCI Inc.
DNB vs MSCI
S&P Global Inc.
DNB vs SPGI
NASDAQ, INC.
DNB vs NDAQ
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe DNB can sustain margin improvement and delever toward MORN-like balance sheet quality, then a selective long position is reasonable because the implied valuation sits near the low end of MORN and DCF ranges; otherwise, MORN’s superior growth, profitability, and ROIC make DNB look like a lower-quality relative value idea.
DNB’s implied price of $15.93 sits within both MORN implied range ($15.77-$19.50) and the DCF range ($16.36-$22.13), suggesting the stock is not clearly dislocated versus either framework. The gap appears driven more by DNB’s weaker earnings quality and balance sheet metrics than by a simple multiple mismatch.
Supporting Metrics